Dr Sophie Adjalley | Postdoctoral Fellow

Adjalley, Sophie

Sophie's postdoctoral research in Marcus Lee’s group focuses on the development of tools to target and regulate the genome of the malaria parasite P. falciparum. Her ultimate objective is to exploit such tools to investigate the mechanisms underlying transcription regulation in this human pathogen and identify new therapeutic targets.

Molecular biologist by training, I am especially interested in investigating the fundamental biology of the human malaria parasite P. falciparum. I completed a PhD in Microbiology and Immunology at Columbia University in New York and conducted my thesis work in the lab of David Fidock. There I investigated the transcriptional changes associated with the acquisition of antimalaria-drug resistance mutations in P. falciparum and established assays for the identification of malaria transmission-blocking compounds. I then joined the group of Lars Steinmetz at the EMBL in Heidelberg, Germany as an EMBL Interdisciplinary Postdoctoral (EIPOD) fellow, where I worked on the epigenetic profiling of chromatin-associated mutants in S. cerevisiae and on the study of transcription initiation in P. falciparum using genome-wide approaches. In September 2015, I joined Marcus Lee's group in the Malaria Programme at the Sanger Institute as a postdoctoral fellow to work on the development of modified versions of the now ubiquitous CRISPR/Cas editing system that will enable the targeting of specific genomic loci for activation or repression of gene expression in P. falciparum. My aim is to then use such tools to investigate the mechanisms controlling transcription initiation in the malaria parasite and possibly identify novel molecular therapeutics.


  • Landscape and Dynamics of Transcription Initiation in the Malaria Parasite Plasmodium falciparum.

    Adjalley SH, Chabbert CD, Klaus B, Pelechano V and Steinmetz LM

    Cell reports 2016;14;10;2463-75

  • Genome-wide transcriptome profiling reveals functional networks involving the Plasmodium falciparum drug resistance transporters PfCRT and PfMDR1.

    Adjalley SH, Scanfeld D, Kozlowski E, Llinás M and Fidock DA

    BMC genomics 2015;16;1090

  • A high-throughput ChIP-Seq for large-scale chromatin studies.

    Chabbert CD, Adjalley SH, Klaus B, Fritsch ES, Gupta I et al.

    Molecular systems biology 2015;11;1;777

  • Plasmodium falciparum phosphoethanolamine methyltransferase is essential for malaria transmission.

    Bobenchik AM, Witola WH, Augagneur Y, Nic Lochlainn L, Garg A et al.

    Proceedings of the National Academy of Sciences of the United States of America 2013;110;45;18262-7

  • Identification of MMV malaria box inhibitors of plasmodium falciparum early-stage gametocytes using a luciferase-based high-throughput assay.

    Lucantoni L, Duffy S, Adjalley SH, Fidock DA and Avery VM

    Antimicrobial agents and chemotherapy 2013;57;12;6050-62

  • Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue.

    Adjalley SH, Johnston GL, Li T, Eastman RT, Ekland EH et al.

    Proceedings of the National Academy of Sciences of the United States of America 2011;108;47;E1214-23

Adjalley, Sophie
Sophie's Timeline

New member of Marcus Lee's research team within the Malaria Program of the Sanger Institute - Development of a CRISPR/cas system to regulate the P. falciparum genome.


Joined the Steinmetz Lab at the EMBL - Heidelberg as an EIPOD (Cofund/Marie Curie Interdisciplinary Postdoctoral) Fellow - Epigenetic and Transcriptomic studies in S. cerevisiae and P. falciparum.

Awarded a PhD in Microbiology and Immunology from Columbia University of New York (NY, USA) - Thesis work conducted in the Fidock Lab on Transcription and antimalarial drug resistance in P. falciparum.


M.S. in Microbiology and Immunology from Albert Einstein College of Medicine, New York, NY (USA)